Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Nasal Spray For Frequent Nighttime Urination Faces Review Hurdles

Executive Summary

Advisory committee will weigh in on desmopressin as FDA questions broad indication and says clinical meaningfulness of treatment effects for Serenity Pharmaceuticals/Allergan’s product vs. placebo are unclear.


Related Content

Desmopressin Battle: Ferring Asks FDA To Reject Serenity's Nocturia Drug
Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod
Ferring’s Nocdurna Nixed By FDA Panel, But Gets Multiple Paths Forward
Allergan Buys Global Rights To Serenity's Phase III Drug For Frequent Nighttime Urination


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts